CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Richon, V. M.
Right arrow Articles by Marks, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Richon, V. M.
Right arrow Articles by Marks, P. A.

Cell Growth & Differentiation, Vol 3, Issue 7 413-420, Copyright © 1992 by American Association of Cancer Research


ARTICLES

Expression and phosphorylation of the retinoblastoma protein during induced differentiation of murine erythroleukemia cells

VM Richon, RA Rifkind and PA Marks
DeWitt Wallace Research Laboratory, Memorial Sloan-Kettering Cancer Center, Cornell University, New York, New York 10021.

Phosphorylation and dephosphorylation of the retinoblastoma protein, pRB, play a role in the control of cell cycle progression and expression of differentiation in eukaryotic cells. The regulation of pRB level and phosphorylation state was investigated during the induction of differentiation of murine erythroleukemia cells (MELC) by the chemical agent hexamethylene bisacetamide (HMBA). In MELC, there is a critical time in G1 or early S phase when HMBA must be present in order to induce differentiation. This is followed by prolongation of the subsequent G1 phase, resumption of progression through the cell cycle for several generations, and then cell cycle arrest in G1-G0. Associated with HMBA-induced prolongation of G1, there is an increase in the amount of the underphosphorylated form of pRB. A variant cell line (DS19/VCR-C) with accelerated kinetics of HMBA-mediated differentiation shows a more marked increase in underphosphorylated pRB. In culture with HMBA, as MELC resume progression through the cell cycle, pRB is present in the phosphorylated form. The total amount of pRB increases approximately 3-fold over the succeeding cell divisions prior to terminal arrest in G1. This increase in pRB is inhibited by dexamethasone, which also blocks HMBA-induced MELC differentiation. During this period, RB mRNA also increases approximately 3- to 5-fold, which reflects an increase in the rate of transcription, with no change in mRNA stability. The state of phosphorylation and amount of pRB appear to be involved in the control of HMBA-induced terminal cell division of MELC.


This article has been cited by other articles:


Home page
Cancer Res.Home page
P. N. Munster, T. Troso-Sandoval, N. Rosen, R. Rifkind, P. A. Marks, and V. M. Richon
The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Induces Differentiation of Human Breast Cancer Cells
Cancer Res., December 1, 2001; 61(23): 8492 - 8497.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
N. O. Fortunel, A. Hatzfeld, and J. A. Hatzfeld
Transforming growth factor-beta : pleiotropic role in the regulation of hematopoiesis
Blood, September 15, 2000; 96(6): 2022 - 2036.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Kimura, M. Ohmichi, H. Kurachi, H. Ikegami, J. Hayakawa, K. Tasaka, Y. Kanda, Y. Nishio, H. Jikihara, N. Matsuura, et al.
Role of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase Cascade in Gonadotropin-releasing Hormone-induced Growth Inhibition of a Human Ovarian Cancer Cell Line
Cancer Res., October 1, 1999; 59(20): 5133 - 5142.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
M. Alcalay, L. Tomassoni, E. Colombo, S. Stoldt, F. Grignani, M. Fagioli, L. Szekely, K. Helin, and P. G. Pelicci
The Promyelocytic Leukemia Gene Product (PML) Forms Stable Complexes with the Retinoblastoma Protein
Mol. Cell. Biol., February 1, 1998; 18(2): 1084 - 1093.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
S. Desrivieres, S. Volarevic, L. Mercep, and S. Ferrari
Evidence for Different Mechanisms of Growth Inhibition of T-cell Lymphoma by Phorbol Esters and Concanavalin A
J. Biol. Chem., January 24, 1997; 272(4): 2470 - 2476.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
S. Salzberg, A. Heller, J. P. Zou, F. R. Collart, and E. Huberman
Interferon-independent activation of (2'-5') oligoadenylate synthetase in Friend erythroleukemia cell variants exposed to HMBA
J. Cell Sci., June 1, 1996; 109(6): 1517 - 1526.
[Abstract] [PDF]


Home page
J Biol ChemHome page
O.-S. Bang, F. W. Ruscetti, M.-H. Lee, S.-J. Kim, and M. C. Birchenall-Roberts
Transforming Growth Factor-1 Modulates p107 Function in Myeloid Cells: CORRELATION WITH CELL CYCLE PROGRESSION
J. Biol. Chem., March 29, 1996; 271(13): 7811 - 7819.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
K F Macleod, N Sherry, G Hannon, D Beach, T Tokino, K Kinzler, B Vogelstein, and T Jacks
p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage.
Genes & Dev., April 15, 1995; 9(8): 935 - 944.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1992 by the American Association of Cancer Research.